Skip to main content
EJNMMI Research
Fig. 2 | EJNMMI Research

Fig. 2

From: Discovery and characterization of a high-affinity and high-specificity peptide ligand LXY30 for in vivo targeting of α3 integrin-expressing human tumors

Fig. 2

Synthesis and chemical structures of several peptide conjugates and binding specificity of LXY30 to U-87MG cells. The synthesis and chemical structures of peptide conjugates LXY30-biotin, LXY30-FITC, and scrambled-LXY30-FITC (S-LXY30-FITC) used for in vitro and in vivo characterization, as well as imaging studies were shown (a). U-87MG cells demonstrated obvious α3β1 integrin expression (b). The binding of 20 nM LXY30-biotin (blue curve) to U-87MG cells could be prevented by pre-incubating the cells with 20 μg anti-α3 antibody (red curve), or 100 μM free LXY30 (green curve), but not 20 μg anti-β1 antibody (orange curve) for 30 min before adding the LXY30-biotin (c). Compared with the negative control (black curve), LXY30-FITC (red curve), but not S-LXY30-FITC (blue curve), binds specifically to α3β1 integrin-expressing glioblastoma U-87MG cells (d)

Back to article page